Education
About Us
Working with TipRanks
Follow Us
Cosmo Bio Co., Ltd. (JP:3386)
:3386
Top Page
Cosmo Bio Co., Ltd.
(3386)
Select Model
Select Model
Rating:64Neutral
Price Target:
¥1,257.00
▲(2.95% Upside)
Cosmo Bio Co., Ltd.'s overall stock score is driven primarily by its strong financial stability, despite challenges in profitability and cash flow. The stock's technical indicators suggest overbought conditions, posing a risk of short-term correction. High P/E ratio indicates potential overvaluation, though the attractive dividend yield offers some compensating benefit.
Cosmo Bio Co., Ltd. (3386) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥7.07B
Dividend Yield5%
Average Volume (3M)4.29K
Price to Earnings (P/E)27.5
Beta (1Y)0.27
Revenue Growth6.93%
EPS Growth-23.49%
CountryJP
Employees174
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)6.81
Shares Outstanding6,048,000
10 Day Avg. Volume2,620
30 Day Avg. Volume4,293
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,257.00Price Target Upside2.95% Upside
Rating ConsensusHold
Number of Analyst Covering1
Cosmo Bio Co., Ltd. Business Overview & Revenue Model
Company DescriptionCosmo Bio Co., Ltd. (3386) is a Japan-based company primarily engaged in the distribution and sale of life science research products. The company offers a comprehensive range of reagents, instruments, and consumables for biotechnology and life science research. Cosmo Bio Co., Ltd. focuses on providing high-quality products sourced from both domestic and international manufacturers, catering to the needs of academic institutions, research laboratories, and pharmaceutical companies.
How the Company Makes MoneyCosmo Bio Co., Ltd. generates revenue through the sale of life science research products, including reagents, instruments, and consumables. The company partners with a variety of manufacturers worldwide to distribute their products in Japan. Key revenue streams include direct sales to research institutions and laboratories, as well as partnerships with international suppliers that allow Cosmo Bio to offer a diverse product range. The company also benefits from its established relationships with academic and pharmaceutical sectors, ensuring a steady demand for its products. Additionally, Cosmo Bio may engage in exclusive distribution agreements or collaborations with manufacturers to enhance its product offerings and maintain its competitive edge in the life sciences market.
Cosmo Bio Co., Ltd. Financial Statement Overview
Summary
Cosmo Bio Co., Ltd. exhibits a stable financial position with strong equity and low leverage, as evidenced by a high equity ratio and low debt-to-equity ratio. However, the company faces declining profitability and cash flow metrics, with a significant decrease in net profit margin and free cash flow, necessitating improvements in operational efficiency.Income Statement
Cosmo Bio Co., Ltd. has shown a stable revenue growth over the years with a slight decrease in the latest year. Gross Profit Margin remains strong at 33.17% for 2024, reflecting efficient cost management. However, the net profit margin has decreased to 2.61% in 2024 from 4.73% in 2023, indicating increased expenses or reduced profitability. EBIT and EBITDA margins are lower compared to previous years, suggesting reduced operational efficiency.72
Positive
Balance Sheet
The company's balance sheet is robust with a high equity ratio of 76.44% in 2024, indicating low leverage and financial stability. The Debt-to-Equity ratio is exceptionally low at 0.0022, which is favorable. Return on Equity has decreased to 2.92% in 2024 from 5.23% in 2023, suggesting reduced profitability relative to equity.85
Very Positive
Cash Flow
Free Cash Flow has decreased significantly by 96.07% from 2023 to 2024, indicating potential cash flow issues. Operating Cash Flow to Net Income ratio is 0.92, suggesting good cash generation relative to net income. The Free Cash Flow to Net Income ratio is low at 0.10, reflecting less efficient cash conversion.68
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.19B | 10.04B | 9.34B | 9.55B | 9.23B | 8.09B |
| Gross Profit | 3.40B | 3.33B | 3.25B | 3.44B | 3.66B | 3.15B |
| EBITDA | 490.00M | 455.00M | 801.00M | 931.00M | 1.26B | 1.18B |
| Net Income | 245.00M | 262.00M | 442.00M | 517.00M | 737.00M | 674.00M |
Balance Sheet | ||||||
| Total Assets | 11.52B | 11.72B | 10.87B | 10.31B | 10.07B | 9.64B |
| Cash, Cash Equivalents and Short-Term Investments | 2.50B | 2.69B | 3.02B | 3.04B | 3.56B | 3.26B |
| Total Debt | 345.00M | 20.00M | 20.00M | 20.00M | 20.00M | 20.00M |
| Total Liabilities | 2.16B | 2.17B | 1.85B | 1.70B | 1.75B | 1.78B |
| Stockholders Equity | 8.76B | 8.97B | 8.45B | 8.05B | 7.79B | 7.36B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 25.00M | 636.00M | 180.00M | 507.00M | 738.00M |
| Operating Cash Flow | 0.00 | 241.00M | 736.00M | 284.00M | 648.00M | 803.00M |
| Investing Cash Flow | 0.00 | -217.00M | -758.00M | -291.00M | -145.00M | 42.00M |
| Financing Cash Flow | 0.00 | -479.00M | -201.00M | -236.00M | -420.00M | -97.00M |
Cosmo Bio Co., Ltd. Technical Analysis
Positive
1221.00
Price Trends
1192.72
Positive
1168.64
Positive
1127.14
Positive
Market Momentum
10.61
Positive
55.25
Neutral
26.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3386, the sentiment is Positive. The current price of 1221 is above the 20-day moving average (MA) of 1216.85, above the 50-day MA of 1192.72, and above the 200-day MA of 1127.14, indicating a bullish trend. The MACD of 10.61 indicates Positive momentum. The RSI at 55.25 is Neutral, neither overbought nor oversold. The STOCH value of 26.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3386.
Cosmo Bio Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥70.94B | 14.01 | 12.31% | 2.93% | 27.28% | 18.29% | |
64 Neutral | ¥7.07B | 27.46 | ― | 5.00% | 6.93% | -23.49% | |
44 Neutral | ¥16.28B | -6.77 | -61.22% | ― | -9.04% | 2.12% | |
42 Neutral | ¥4.81B | -5.48 | ― | ― | 27.46% | 20.63% | |
41 Neutral | ¥9.50B | -5.12 | ― | ― | -82.19% | -106.15% | |
41 Neutral | ¥7.88B | -11.25 | ― | ― | -96.99% | 29.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:3386
Cosmo Bio Co., Ltd.
1,221.00
159.56
15.03%
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,703.00
517.00
43.59%
JP:4586
Medrx Co., Ltd.
146.00
48.00
48.98%
JP:4588
Oncolys BioPharma, Inc.
630.00
53.00
9.19%
JP:4882
Perseus Proteomics, Inc.
320.00
-332.00
-50.92%
JP:4893
Noile-Immune Biotech Inc.
180.00
-29.00
-13.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.